Yellow subthreshold micropulse laser treatment in diabetic macular edema-preliminary results Diyabetik makula ödeminde sari eşik alti mikropuls laser tedavisi-ilk sonuçlar
Retina-Vitreus, cilt.26, sa.3, ss.228-231, 2017 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 3
- Basım Tarihi: 2017
- Dergi Adı: Retina-Vitreus
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.228-231
- Anahtar Kelimeler: Diabetic macular edema, Micropulse laser, Subthreshold laser, Yellow laser
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: To assess the efficacy of 577nm subthreshold yellow wavelength micropulse laser (MPL) in our patients with diabetic macular edema (DME). Material and Methods: Retrospective case series. A single session of subthreshold 577nm yellow wavelength MPL treatment was performed in 23 eyes of 18 patients with center involved DME. In all but one patient, previous intravitreal anti vascular endothelial growth factor (IV anti-VEGF) and/or IV steroid treatment and/or conventional laser treatment had been performed. In patients with > 300μ central macular thickness (CMT) at the first control visit, IV anti-VEGF treatment was performed if deemed necessary. Treatment efficacy was evaluated by comparing CMT and best corrected visual acuity (BCVA) before treatment and at first and second control visits and assessing the ratio of patients with CMT ≤ 300μ or whose CMT decreased at least 10% at first control visit compared to pre-treatment. Results: CMT was not found different when compared between pre and post-treatment at first control visit. A significant decrease in CMT was assessed at second visit. CMT decreased at least 10% or was 300μ or less at first visit post-treatment. BCVA was not found different at first and second visits compared to pre-treatment. Conclusion: Yellow subthreshold MPL treatment might be effective in DME solely or additional to anti-VEGF agents. Its role in treatment should be better assessed by prospective controlled studies.